On January 29, the National Drug Administration of China (NMPA) announced the conditional use license for 2 domestic drugs. COVID-19 treatment including SIM0417 and VV116.
Ecns.cn (China) news network cited NMPA’s announcement that both oral drugs SIM0417 and VV116 can be used to treat adult COVID-19 patients with mild or moderate symptoms. Patients are advised to use the drug strictly according to the doctor’s instructions.
Medicine SIM0417by Simcere Group in Nanjing, Shanghai Pharmaceutical Research Institute and Wuhan Institute of Virology under the Institute of Scientific Research Chinaco-developer.
[COVID-19: Trung Quốc cấp phép sử dụng có điều kiện thuốc Molnupiravir]
The drug works by targeting an enzyme that plays an important role in replication and in the life cycle of corona virus strains, including SARS-CoV-2.
Meanwhile, VV116 was evaluated to be as effective as Paxlovid in speeding up clinical recovery. Participating in the development of VV116 are units under the Chinese Academy of Sciences.
NMPA also requires developers to continue to add research results by specific deadlines.
Le Anh (VNA/Vietnam+)
